Sobi Patent-Cliff Exposure & CMS Drug Spending Portfolio

Sobi (US): 1 reconciled FDA prescription therapies (100.0% 2025 to 2030 cliff risk), $116.3M 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Headquarters / ClusterUS
Reconciled FDA Portfolio Therapies1
2025 to 2030 Patent-Cliff Revenue Exposure100.0%
Primary Portfolio LOE Date2030-01-01
2024 CMS Total Public Spend$116.3M
2024 Medicare Part D Spend$110.8M
2024 Medicaid Spend$5.5M
California HCAI SB 17 Filings2 WAC filings (max 32.7% 2-yr change)